Phase II Evaluation of Bolus Gallium Nitrate in Lymphoproliferative Disorders: A Southeastern Cancer Study Group Trial

Cancer Treat Rep. 1986 Oct;70(10):1221-3.

Abstract

Gallium nitrate was administered as a 700-mg/m2 iv bolus infusion over 15-30 minutes every 2 weeks to 138 patients with malignant lymphoproliferative diseases. Responses occurred in patients with well-differentiated lymphomas (five responses among eight patients), but the drug produced few responses in any other group of patients. Toxic effects were primarily gastrointestinal and reversible renal abnormalities and anemia. As a single agent, bolus gallium nitrate has little activity in lymphoproliferative diseases.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Evaluation
  • Gallium / adverse effects
  • Gallium / therapeutic use*
  • Humans
  • Lymphoma / drug therapy*
  • Middle Aged

Substances

  • Antineoplastic Agents
  • Gallium
  • gallium nitrate